Tasigna (Chronic Myeloid Leukemia)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 11
3.1.3 Clinical Staging 13
3.1.4 Prognosis 14
3.1.5 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 17
4.1 Global Trends 17
4.1.1 Treatment Overview 17
4.1.2 Diagnostic Tests 20
4.1.3 Genetic Testing 21
4.1.4 Monitoring Patient Response to Treatment 23
4.1.5 Future Directions: Discontinuation Therapy 26
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Product Profile – Tasigna (nilotinib) 32
6.1 Overview 32
6.2 Efficacy 34
6.3 Safety 35
6.4 SWOT Analysis 36
6.5 Forecast 37
7 Appendix 38
7.1 Bibliography 38
7.2 Abbreviations 40
7.3 Methodology 43
7.4 Forecasting Methodology 43
7.4.1 Diagnosed CML patients 43
7.4.2 Drug-treated Patients on X Line of Therapy 44
7.4.3 General Pricing Assumptions 44
7.4.4 Compliance Assumptions for Oral TKIs 46
7.4.5 Individual Drug Assumptions 47
7.4.6 Generic Erosion 47
7.4.7 Pricing of New Market Entrants 47
7.5 Physicians and Specialists Included in this Study 48
7.6 Survey of High Prescribing Physicians 49
7.7 About the Authors 50
7.7.1 Authors 50
7.7.2 Epidemiologists 51
7.7.3 Global Director of Epidemiology and Clinical Trials Analysis 52
7.7.4 Global Head of Healthcare 53
7.8 About GlobalData 54
7.9 Contact Us 54
7.10 Disclaimer 54